# EmergingMed.com

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/emergingmed-com

- Industry: Healthcare IT
- Headquarters: New York, US
- Website: www.emergingmed.com
- Total disclosed funding: $3M
- Latest round: Series B (Jan 5, 2006)
- Investors on record: 4

## About

EmergingMed.com Inc. provides a digital platform that connects patients and caregivers to clinical trials, facilitating access to innovative treatment options for various medical conditions.Founded in 2000, EmergingMed.com Inc. is headquartered in New York, US, specializing in clinical trial engagement. The company raised USD 3 million in Series B funding on January 5, 2006, led by Advantage Capital Partners, with participation from Florida Gulfshore Capital, Rand Capital, and Spring Bay Companies. The founders, Courtney Hudson and Brian Weiss, have a background in creating solutions for patient access to clinical trials.EmergingMed.com Inc. offers Carebox Connect, a digital platform designed to facilitate the discovery and engagement with clinical trials for patients and caregivers. Users can search and filter clinical trials based on criteria like condition, location, and trial identifiers, targeting patients seeking new treatment options, caregivers, and healthcare professionals. The company primarily serves North American and European markets across various medical conditions and therapeutic areas.EmergingMed.com Inc. generates revenue through partnerships with healthcare providers conducting clinical trials, utilizing a model based on subscription services. Clients, including healthcare professionals and organizations, subscribe to access the platform and the trial management tools, contributing significantly to the company’s revenue streams by enhancing connections between patients and ongoing research.The funds raised in January 2006 will support the development of new product features within Carebox Connect, enhancing user experience and engagement in clinical trials. EmergingMed.com Inc. plans to expand its services into additional European markets by 2025, targeting regions with high demand for innovative therapeutic solutions. The recent financing will facilitate these initiatives, ensuring the company can broaden its impact in the clinical trial landscape.

## Funding rounds

- Series B, Jan 5, 2006, $3M — Advantage Capital, Rand Capital Corporation, Spring Bay Companies, Florida Gulfshore Capital

## Investors

- Advantage Capital — Series B
- Rand Capital Corporation (https://capitalatlas.ai/funds/rand-capital-corporation) — Series B
- Spring Bay Companies (https://capitalatlas.ai/funds/spring-bay-companies) — Series B
- Florida Gulfshore Capital (https://capitalatlas.ai/funds/florida-gulfshore-capital) — Series B